@entity1092 ( @entity3262 ) can autoinduce its own metabolism. Cases requiring @entity3262 doses >4000   mg/day to obtain therapeutic plasma concentrations, such as these 3 cases, have never been published. Case 1 received @entity3262 for @entity410 and @entity161 and had >50 @entity3262 concentrations in 4 years. A high dose of 5,250   mg/day of @entity3262 concentrate was prescribed for years but this dose led to an intoxication when switched to the enterocoated @entity1092 formulation, requiring a normal dose of 2000   mg/day. @entity3262 metabolic capacity was significantly higher (t = -9.6; df = 6.3, p < 0.001) during the @entity3262 concentrate therapy, possibly due to autoinduction in that formulation. Case 2 had @entity3262 for @entity716 with 10 @entity3262 concentrations during an 8-week admission. To maintain a @entity3262 level >= 50    g/mL, @entity3262 doses increased from 1500 to 4000   mg/day. Case 3 had @entity2916 and @entity302 and was followed up for >4 years with 137 @entity3262 concentrations. To maintain @entity3262 concentrations >= 50    g/mL, @entity3262 doses increased from 3,375 to 10,500   mg/day. In Cases 2 and 3, the duration of admission and the @entity3262 dose were strongly correlated (r around 0.90; p < 0.001) with almost no change after controlling for @entity3262 concentrations, indicating progressive autoinduction that increased with time.

Three patients needing high doses of XXXX to get therapeutic concentrations.

@entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity3262 :: ('D014635', 'Chemical') :: ['VPA'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproic acid', 'divalproex sodium'] @entity2916 :: ('MESH:D014402', 'Disease') :: ['tuberous sclerosis'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity716 :: ('MESH:D011605', 'Disease') :: ['schizoaffective psychosis'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']
@entity1092 :: (MESH:D014635,Chemical) :: ['valproic Acid']
